HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Samuel Waxman Selected Research

Drug Therapy (Chemotherapy)

6/2011Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
2/2011Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors.
3/2009Differentiation therapy of acute myeloid leukemia: past, present and future.
5/2005Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.
1/2005Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.
4/2003Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
1/2002Arsenic trioxide in multiple myeloma: rationale and future directions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Samuel Waxman Research Topics

Disease

31Neoplasms (Cancer)
01/2023 - 07/2002
22Acute Promyelocytic Leukemia
03/2016 - 01/2002
10Leukemia
12/2012 - 02/2002
9Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022 - 09/2005
7Sudden Infant Death (SID)
02/2022 - 06/2010
7Breast Neoplasms (Breast Cancer)
01/2022 - 08/2002
5Hematologic Neoplasms (Hematological Malignancy)
12/2006 - 01/2002
4Carcinogenesis
07/2016 - 01/2005
4Lymphoma (Lymphomas)
12/2012 - 04/2003
4Carcinoma (Carcinomatosis)
02/2011 - 01/2005
4Multiple Myeloma
03/2008 - 01/2002
3Hepatocellular Carcinoma (Hepatoma)
05/2011 - 12/2008
2B-Cell Lymphoma (Lymphoma, B Cell)
01/2022 - 12/2012
2Triple Negative Breast Neoplasms
07/2016 - 08/2015
2Inflammation (Inflammations)
04/2015 - 04/2013
2Myeloid Leukemia (Leukemia, Myelocytic)
12/2012 - 03/2005
2Melanoma (Melanoma, Malignant)
01/2005 - 12/2003
2Prostatic Neoplasms (Prostate Cancer)
05/2004 - 12/2003
1Chromosome Aberrations (Chromosome Abnormalities)
01/2017
1Necrosis
06/2011
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2011
1Lung Neoplasms (Lung Cancer)
06/2011
1Progressive Multifocal Leukoencephalopathy
03/2009

Drug/Important Bio-Agent (IBA)

18Arsenic Trioxide (Trisenox)FDA Link
01/2018 - 01/2002
15Tretinoin (Retinoic Acid)FDA LinkGeneric
01/2022 - 02/2002
12Proteins (Proteins, Gene)FDA Link
02/2022 - 08/2002
5Retinoic Acid Receptor alphaIBA
03/2009 - 02/2002
5Aligeron (AS 2)IBA
08/2008 - 04/2003
4Transcription Factors (Transcription Factor)IBA
01/2022 - 12/2006
4Peptides (Polypeptides)IBA
01/2022 - 08/2015
4ChromatinIBA
01/2022 - 03/2008
4RetinoidsIBA
07/2016 - 10/2003
4TamoxifenFDA LinkGeneric
08/2015 - 02/2008
4Co-Repressor ProteinsIBA
08/2015 - 05/2003
4Histone Deacetylase InhibitorsIBA
03/2007 - 08/2002
4promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA
09/2005 - 08/2002
3CytokinesIBA
04/2015 - 01/2005
3Cyclin D1IBA
06/2011 - 09/2006
3ArsenicIBA
03/2009 - 07/2002
2Histone Deacetylases (Histone Deacetylase)IBA
01/2022 - 08/2002
2retinoic acid receptor betaIBA
01/2022 - 06/2010
2Estrogens (Estrogen)FDA Link
08/2015 - 04/2011
2Caspase 3 (Caspase-3)IBA
12/2012 - 03/2005
2Therapeutic UsesIBA
12/2012 - 05/2005
2Caspase 8 (Caspase-8)IBA
11/2012 - 03/2005
2CyclinsIBA
02/2008 - 09/2006
2UbiquitinIBA
05/2007 - 12/2006
2Bortezomib (Velcade)FDA Link
05/2007 - 09/2006
2Proteasome Endopeptidase Complex (Proteasome)IBA
05/2007 - 12/2006
2Proteasome InhibitorsIBA
05/2007 - 09/2006
2Death Domain ReceptorsIBA
12/2006 - 03/2005
2Glutathione S-Transferase piIBA
02/2005 - 05/2004
2Reactive Oxygen Species (Oxygen Radicals)IBA
01/2005 - 12/2003
2InterleukinsIBA
01/2005 - 12/2003
2Butyric Acid (Butanoic Acid)IBA
10/2003 - 08/2002
1Vincristine (Oncovin)FDA LinkGeneric
01/2023
1Paclitaxel (Taxol)FDA LinkGeneric
01/2023
1ColchicineFDA LinkGeneric
01/2023
1LuciferasesIBA
01/2022
1venetoclaxIBA
01/2022
1Cytarabine (Cytosar-U)FDA LinkGeneric
01/2022
1Am 580 (Am580)IBA
01/2022
1Checkpoint Kinase 1IBA
01/2022
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2018
1Sorafenib (BAY 43-9006)FDA Link
01/2018
1CateninsIBA
10/2017
1B7-H1 AntigenIBA
01/2017
1tamibaroteneIBA
07/2016
1A-factor (Streptomyces)IBA
10/2015
1avermectinIBA
08/2015
1selamectinIBA
08/2015
1Ivermectin (Mectizan)FDA Link
08/2015
1ProgesteroneFDA LinkGeneric
08/2015
1TOR Serine-Threonine KinasesIBA
04/2015
1IronIBA
03/2015
1artenimol (dihydroartemisinin)IBA
03/2015
1Apoptosis Regulatory ProteinsIBA
03/2015
1Ethacrynic Acid (Etacrynic Acid)FDA Link
12/2012
1ethacrynic acid butyl esterIBA
12/2012
1Glutathione Transferase (Glutathione S-Transferase)IBA
12/2012
1Cytochromes c (Cytochrome c)IBA
12/2012
1LipidsIBA
11/2012
1Surface Antigens (Surface Antigen)IBA
11/2012
1Cyclin EIBA
06/2011
1Erlotinib Hydrochloride (CP 358,774)FDA Link
06/2011
1Bexarotene (LGD1069)FDA Link
06/2011
1MicroRNAs (MicroRNA)IBA
05/2011
1Fulvestrant (Faslodex)FDA Link
04/2011
1Mucin-1 (CA 15-3 Antigen)IBA
02/2011
1Epithelial Cell Adhesion MoleculeIBA
02/2011
1CollagenIBA
02/2011
1Mitochondrial DNA (mtDNA)IBA
02/2011
1Estrogen Receptor alphaIBA
06/2010
1Cadherins (E-Cadherin)IBA
06/2010
1Oncogene Proteins (Oncogene Protein)IBA
03/2009
1EverolimusFDA Link
12/2008
1AEE 788 (AEE788)IBA
12/2008

Therapy/Procedure

22Therapeutics
01/2023 - 01/2002
7Drug Therapy (Chemotherapy)
06/2011 - 01/2002
1Ligation
11/2012